Mitochondria and Mitochondrial ROS in Cancer: Novel Targets for Anticancer Therapy

Journal of Cellular Physiology

Volumn 231, Issue 12, 2016, Pages 2570-2581

  Yang, Yuhui ^a,b   Karakhanova, Svetlana ^b   Hartwig, Werner ^c   D'Haese, Jan G ^c   Philippov, Pavel P ^d   Werner, Jens ^c   Bazhin, Alexandr V ^c  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d MOSCOW STATE UNIVERSITY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIOXIDANT; MITOCHONDRIAL DNA; PROTEIN; REACTIVE OXYGEN METABOLITE; SKQ1 PROTEIN; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; CANCER CELL; CANCER PREVENTION; CANCER THERAPY; CARCINOGENESIS; CELL METABOLISM; DRUG DELIVERY SYSTEM; DRUG SAFETY; DRUG TARGETING; GENE EXPRESSION; HUMAN; MITOCHONDRIAL GENE; MITOCHONDRION; NEOPLASM; NONHUMAN; NUCLEAR REPROGRAMMING; PHENOTYPIC VARIATION; PRIORITY JOURNAL; REVIEW; STROMA CELL;

EID: 84983360016     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.25349     Document Type: Review

References (147)

1. Acin-Perez R, Gatti DL, Bai Y, Manfredi G. 2011. Protein phosphorylation and prevention of cytochrome oxidase inhibition by ATP: Coupled mechanisms of energy metabolism regulation. Cell metabolism 13:712–719.
2. Adlam VJ, Harrison JC, Porteous CM, James AM, Smith RA, Murphy MP, Sammut IA. 2005. Targeting an antioxidant to mitochondria decreases cardiac ischemia-reperfusion injury. Faseb J 19:1088–1095.
3. Agapova LS, Chernyak BV, Domnina LV, Dugina VB, Efimenko AY, Fetisova EK, Ivanova OY, Kalinina NI, Khromova NV, Kopnin BP, Kopnin PB, Korotetskaya MV, Lichinitser MR, Lukashev AL, Pletjushkina OY, Popova EN, Skulachev MV, Shagieva GS, Stepanova EV, Titova EV, Tkachuk VA, Vasiliev JM, Skulachev VP. 2008. Mitochondria-targeted plastoquinone derivatives as tools to interrupt execution of the aging program. 3. Inhibitory effect of SkQ1 on tumor development from p53-deficient cells. Biochemistry (Mosc) 73:1300–1316.
4. Anso E, Mullen AR, Felsher DW, Mates JM, Deberardinis RJ, Chandel NS. 2013. Metabolic changes in cancer cells upon suppression of MYC. Cancer Metab 1:7.
5. Antanaviciute I, Rysevaite K, Liutkevicius V, Marandykina A, Rimkute L, Sveikatiene R, Uloza V, Skeberdis VA. 2014. Long-distance communication between laryngeal carcinoma cells. PLoS ONE 9:e99196.
6. Antonenko YN, Avetisyan AV, Bakeeva LE, Chernyak BV, Chertkov VA, Domnina LV, Ivanova OY, Izyumov DS, Khailova LS, Klishin SS, Korshunova GA, Lyamzaev KG, Muntyan MS, Nepryakhina OK, Pashkovskaya AA, Pletjushkina OY, Pustovidko AV, Roginsky VA, Rokitskaya TI, Ruuge EK, Saprunova VB, Severina II, Simonyan RA, Skulachev IV, Skulachev MV, Sumbatyan NV, Sviryaeva IV, Tashlitsky VN, Vassiliev JM, Vyssokikh MY, Yaguzhinsky LS, Zamyatnin AA, Jr, Skulachev VP. 2008a. Mitochondria-targeted plastoquinone derivatives as tools to interrupt execution of the aging program. 1. Cationic plastoquinone derivatives: Synthesis and in vitro studies. Biochemistry (Mosc) 73:1273–1287.
7. Antonenko YN, Roginsky VA, Pashkovskaya AA, Rokitskaya TI, Kotova EA, Zaspa AA, Chernyak BV, Skulachev VP. 2008b. Protective effects of mitochondria-targeted antioxidant SkQ in aqueous and lipid membrane environments. J Membr Biol 222:141–149.
8. Basova LV, Kurnikov IV, Wang L, Ritov VB, Belikova NA, Vlasova II, Pacheco AA, Winnica DE, Peterson J, Bayir H, Waldeck DH, Kagan VE. 2007. Cardiolipin switch in mitochondria: Shutting off the reduction of cytochrome c and turning on the peroxidase activity. Biochemistry 46:3423–3434.
9. Belzacq AS, El Hamel C, Vieira HL, Cohen I, Haouzi D, Metivier D, Marchetti P, Brenner C, Kroemer G. 2001. Adenine nucleotide translocator mediates the mitochondrial membrane permeabilization induced by lonidamine, arsenite, and CD437. Oncogene 20:7579–7587.
10. Berridge MV, Dong L, Neuzil J. 2015. Mitochondrial DNA in tumor initiation, progression, and metastasis: Role of horizontal mtDNA transfer. Cancer Res 75:3203–3208.
11. Bonuccelli G, Tsirigos A, Whitaker-Menezes D, Pavlides S, Pestell RG, Chiavarina B, Frank PG, Flomenberg N, Howell A, Martinez-Outschoorn UE, Sotgia F, Lisanti MP. 2010a. Ketones and lactate “fuel” tumor growth and metastasis: Evidence that epithelial cancer cells use oxidative mitochondrial metabolism. Cell Cycle 9:3506–3514.
12. Bonuccelli G, Whitaker-Menezes D, Castello-Cros R, Pavlides S, Pestell RG, Fatatis A, Witkiewicz AK, Vander Heiden MG, Migneco G, Chiavarina B, Frank PG, Capozza F, Flomenberg N, Martinez-Outschoorn UE, Sotgia F, Lisanti MP. 2010b. The reverse Warburg effect: Glycolysis inhibitors prevent the tumor promoting effects of caveolin-1 deficient cancer associated fibroblasts. Cell Cycle 9:1960–1971.
13. Brandon M, Baldi P, Wallace DC. 2006. Mitochondrial mutations in cancer. Oncogene 25:4647–4662.
14. Caicedo A, Fritz V, Brondello JM, Ayala M, Dennemont I, Abdellaoui N, de Fraipont F, Moisan A, Prouteau CA, Boukhaddaoui H, Jorgensen C, Vignais ML. 2015. MitoCeption as a new tool to assess the effects of mesenchymal stem/stromal cell mitochondria on cancer cell metabolism and function. Sci Reports 5:9073.
15. Campello S, Scorrano L. 2010. Mitochondrial shape changes: Orchestrating cell pathophysiology. EMBO Reports 11:678–684.
16. Cao X, Fang L, Gibbs S, Huang Y, Dai Z, Wen P, Zheng X, Sadee W, Sun D. 2007. Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia. Cancer Chemother Pharmacol 59:495–505.
17. Chae YC, Caino MC, Lisanti S, Ghosh JC, Dohi T, Danial NN, Villanueva J, Ferrero S, Vaira V, Santambrogio L, Bosari S, Languino LR, Herlyn M, Altieri DC. 2012. Control of tumor bioenergetics and survival stress signaling by mitochondrial HSP90s. Cancer Cell 22:331–344.
18. Chandel NS. 2014. Mitochondria as signaling organelles. BMC Biol 12:34.
19. Chandran K, Aggarwal D, Migrino RQ, Joseph J, McAllister D, Konorev EA, Antholine WE, Zielonka J, Srinivasan S, Avadhani NG, Kalyanaraman B. 2009. Doxorubicin inactivates myocardial cytochrome c oxidase in rats: Cardioprotection by Mito-Q. Biophys J 96:1388–1398.
20. Chang SC, Lin PC, Yang SH, Wang HS, Liang WY, Lin JK. 2009. Mitochondrial D-loop mutation is a common event in colorectal cancers with p53 mutations. Int J Colorectal Dis 24:623–628.
21. Chatterjee A, Dasgupta S, Sidransky D. 2011. Mitochondrial subversion in cancer. Cancer Prev Res 4:638–654.
22. Chatterjee A, Mambo E, Sidransky D. 2006. Mitochondrial DNA mutations in human cancer. Oncogene 25:4663–4674.
23. Chen X, Qian Y, Wu S. 2015. The Warburg effect: Evolving interpretations of an established concept. Free Radical Biol Med 79:253–263.
24. Choi SY, Gonzalvez F, Jenkins GM, Slomianny C, Chretien D, Arnoult D, Petit PX, Frohman MA. 2007. Cardiolipin deficiency releases cytochrome c from the inner mitochondrial membrane and accelerates stimuli-elicited apoptosis. Cell Death Differ 14:597–606.
25. Christofk HR, Vander Heiden MG, Wu N, Asara JM, Cantley LC. 2008. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 452:181–186.
26. Coller HA, Khrapko K, Bodyak ND, Nekhaeva E, Herrero-Jimenez P, Thilly WG. 2001. High frequency of homoplasmic mitochondrial DNA mutations in human tumors can be explained without selection. Nature Genet 28:147–150.
27. Costantini P, Belzacq AS, Vieira HL, Larochette N, de Pablo MA, Zamzami N, Susin SA, Brenner C, Kroemer G. 2000. Oxidation of a critical thiol residue of the adenine nucleotide translocator enforces Bcl-2-independent permeability transition pore opening and apoptosis. Oncogene 19:307–314.
28. Don AS, Kisker O, Dilda P, Donoghue N, Zhao X, Decollogne S, Creighton B, Flynn E, Folkman J, Hogg PJ. 2003. A peptide trivalent arsenical inhibits tumor angiogenesis by perturbing mitochondrial function in angiogenic endothelial cells. Cancer Cell 3:497–509.
29. Fantin VR, St-Pierre J, Leder P. 2006. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 9:425–434.
30. Fetisova EK, Avetisyan AV, Izyumov DS, Korotetskaya MV, Chernyak BV, Skulachev VP. 2010. Mitochondria-targeted antioxidant SkQR1 selectively protects MDR (Pgp 170)-negative cells against oxidative stress. FEBS Lett 584:562–566.
31. Fliss MS, Usadel H, Caballero OL, Wu L, Buta MR, Eleff SM, Jen J, Sidransky D. 2000. Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science 287:2017–2019.
32. Fulda S, Galluzzi L, Kroemer G. 2010. Targeting mitochondria for cancer therapy. Nature Rev Drug Discov 9:447–464.
33. Galluzzi L, Kroemer G. 2008. Necroptosis: A specialized pathway of programmed necrosis. Cell 135:1161–1163.
34. Gane EJ, Weilert F, Orr DW, Keogh GF, Gibson M, Lockhart MM, Frampton CM, Taylor KM, Smith RA, Murphy MP. 2010. The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients. Liver Int 30:1019–1026.
35. Gao P, Zhang H, Dinavahi R, Li F, Xiang Y, Raman V, Bhujwalla ZM, Felsher DW, Cheng L, Pevsner J, Lee LA, Semenza GL, Dang CV. 2007. HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell 12:230–238.
36. Gogvadze V, Orrenius S, Zhivotovsky B. 2008. Mitochondria in cancer cells: What is so special about them? Trends Cell Biol 18:165–173.
37. Gogvadze V, Orrenius S, Zhivotovsky B. 2009. Mitochondria as targets for cancer chemotherapy. Semin Cancer Biol 19:57–66.
38. Goto M, Miwa H, Suganuma K, Tsunekawa-Imai N, Shikami M, Mizutani M, Mizuno S, Hanamura I, Nitta M. 2014. Adaptation of leukemia cells to hypoxic condition through switching the energy metabolism or avoiding the oxidative stress. BMC Cancer 14:76.
39. Gozuacik D, Kimchi A. 2004. Autophagy as a cell death and tumor suppressor mechanism. Oncogene 23:2891–2906.
40. Graham D, Huynh NN, Hamilton CA, Beattie E, Smith RA, Cocheme HM, Murphy MP, Dominiczak AF. 2009. Mitochondria-targeted antioxidant MitoQ10 improves endothelial function and attenuates cardiac hypertrophy. Hypertension 54:322–328.
41. Green DE. 1974. The electromechanochemical model for energy coupling in mitochondria. Biochim Biophys Acta 346:27–78.
42. Guzy RD, Sharma B, Bell E, Chandel NS, Schumacker PT. 2008. Loss of the SdhB, but Not the SdhA, subunit of complex II triggers reactive oxygen species-dependent hypoxia-inducible factor activation and tumorigenesis. Mol Cell Biol 28:718–731.
43. Hamanaka RB, Chandel NS. 2010. Mitochondrial reactive oxygen species regulate cellular signaling and dictate biological outcomes. Trends Biochem Sci 35:505–513.
44. Higuchi M, Aggarwal BB, Yeh ET. 1997. Activation of CPP32-like protease in tumor necrosis factor-induced apoptosis is dependent on mitochondrial function. J Clin Invest 99:1751–1758.
45. Hitosugi T, Kang S, Vander Heiden MG, Chung TW, Elf S, Lythgoe K, Dong S, Lonial S, Wang X, Chen GZ, Xie J, Gu TL, Polakiewicz RD, Roesel JL, Boggon TJ, Khuri FR, Gilliland DG, Cantley LC, Kaufman J, Chen J. 2009. Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal 2:ra73.
46. Hofhaus G, Berneburg M, Wulfert M, Gattermann N. 2003. Live now-pay by ageing: High performance mitochondrial activity in youth and its age-related side effects. Exp Physiol 88:167–174.
47. Hofhaus G, Gattermann N. 1999. Mitochondria harbouring mutant mtDNA—A cuckoo in the nest? Biol Chem 380:871–877.
48. Horton KL, Stewart KM, Fonseca SB, Guo Q, Kelley SO. 2008. Mitochondria-penetrating peptides. Chem Biol 15:375–382.
49. Hu Y, Lu W, Chen G, Wang P, Chen Z, Zhou Y, Ogasawara M, Trachootham D, Feng L, Pelicano H, Chiao PJ, Keating MJ, Garcia-Manero G, Huang P. 2012. K-ras(G12V) transformation leads to mitochondrial dysfunction and a metabolic switch from oxidative phosphorylation to glycolysis. Cell Res 22:399–412.
50. Huang P, Feng L, Oldham EA, Keating MJ, Plunkett W. 2000. Superoxide dismutase as a target for the selective killing of cancer cells. Nature 407:390–395.
51. Imanishi H, Hattori K, Wada R, Ishikawa K, Fukuda S, Takenaga K, Nakada K, Hayashi J. 2011. Mitochondrial DNA mutations regulate metastasis of human breast cancer cells. PLoS ONE 6:e23401.
52. Ishikawa K, Takenaga K, Akimoto M, Koshikawa N, Yamaguchi A, Imanishi H, Nakada K, Honma Y, Hayashi J. 2008. ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science 320:661–664.
53. Izyumov DS, Domnina LV, Nepryakhina OK, Avetisyan AV, Golyshev SA, Ivanova OY, Korotetskaya MV, Lyamzaev KG, Pletjushkina OY, Popova EN, Chernyak BV. 2010. Mitochondria as source of reactive oxygen species under oxidative stress. Study with novel mitochondria-targeted antioxidants-the “Skulachev-ion” derivatives. Biochemistry (Mosc) 75:123–129.
54. James AM, Cocheme HM, Smith RA, Murphy MP. 2005. Interactions of mitochondria-targeted and untargeted ubiquinones with the mitochondrial respiratory chain and reactive oxygen species. Implications for the use of exogenous ubiquinones as therapies and experimental tools. J Biol Chem 280:21295–21312.
55. Jose C, Bellance N, Rossignol R. 2011. Choosing between glycolysis and oxidative phosphorylation: A tumor's dilemma? Biochim Biophys Acta 1807:552–561.
56. K CS, Carcamo JM, Golde DW. 2006. Antioxidants prevent oxidative DNA damage and cellular transformation elicited by the over-expression of c-MYC. Mutation Res 593:64–79.
57. Kaelin WG, Jr., McKnight SL. 2013. Influence of metabolism on epigenetics and disease. Cell 153:56–69.
58. Kelso GF, Porteous CM, Coulter CV, Hughes G, Porteous WK, Ledgerwood EC, Smith RA, Murphy MP. 2001. Selective targeting of a redox-active ubiquinone to mitochondria within cells: Antioxidant and antiapoptotic properties. J Biol Chem 276:4588–4596.
59. Kim MM, Clinger JD, Masayesva BG, Ha PK, Zahurak ML, Westra WH, Califano JA. 2004. Mitochondrial DNA quantity increases with histopathologic grade in premalignant and malignant head and neck lesions. Clin Cancer Res 10:8512–8515.
60. Klaunig JE, Kamendulis LM. 2004. The role of oxidative stress in carcinogenesis. Ann Rev Pharmacol Toxicol 44:239–267.
61. Klaunig JE, Wang Z, Pu X, Zhou S. 2011. Oxidative stress and oxidative damage in chemical carcinogenesis. Toxicol Appl Pharmacol 254:86–99.
62. Lee HC, Yin PH, Lu CY, Chi CW, Wei YH. 2000. Increase of mitochondria and mitochondrial DNA in response to oxidative stress in human cells. Biochem J 348:425–432.
63. Leonard JV, Morris AA. 2000. Inborn errors of metabolism around time of birth. Lancet 356:583–587.
64. Leonard JV, Schapira AH. 2000. Mitochondrial respiratory chain disorders II: Neurodegenerative disorders and nuclear gene defects. Lancet 355:389–394.
65. Liberman EA, Topaly VP, Tsofina LM, Jasaitis AA, Skulachev VP. 1969. Mechanism of coupling of oxidative phosphorylation and the membrane potential of mitochondria. Nature 222:1076–1078.
66. Linehan WM, Rouault TA. 2013. Molecular pathways: Fumarate hydratase-deficient kidney cancer–targeting the Warburg effect in cancer. Clin Cancer Res 19:3345–3352.
67. Liou GY, Storz P. 2010. Reactive oxygen species in cancer. Free Radical Res 44:479–496.
68. Liu L, Trimarchi JR, Smith PJ, Keefe DL. 2002. Mitochondrial dysfunction leads to telomere attrition and genomic instability. Aging Cell 1:40–46.
69. Lv L, Li D, Zhao D, Lin R, Chu Y, Zhang H, Zha Z, Liu Y, Li Z, Xu Y, Wang G, Huang Y, Xiong Y, Guan KL, Lei QY. 2011. Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth. Mol Cell 42:719–730.
70. Martinez-Outschoorn UE, Balliet RM, Rivadeneira DB, Chiavarina B, Pavlides S, Wang C, Whitaker-Menezes D, Daumer KM, Lin Z, Witkiewicz AK, Flomenberg N, Howell A, Pestell RG, Knudsen ES, Sotgia F, Lisanti MP. 2010. Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution: A new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells. Cell Cycle 9:3256–3276.
71. Martinez-Outschoorn UE, Pavlides S, Howell A, Pestell RG, Tanowitz HB, Sotgia F, Lisanti MP. 2011. Stromal-epithelial metabolic coupling in cancer: Integrating autophagy and metabolism in the tumor microenvironment. Int J Biochem Cell Biol 43:1045–1051.
72. Metallo CM, Gameiro PA, Bell EL, Mattaini KR, Yang J, Hiller K, Jewell CM, Johnson ZR, Irvine DJ, Guarente L, Kelleher JK, Vander Heiden MG, Iliopoulos O, Stephanopoulos G. 2012. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 481:380–384.
73. Mishra P, Chan DC. 2014. Mitochondrial dynamics and inheritance during cell division, development and disease. Nature Rev Mol Cell Biol 15:634–646.
74. Modica-Napolitano JS, Singh KK. 2004. Mitochondrial dysfunction in cancer. Mitochondrion 4:755–762.
75. Modica-Napolitano JS, Weissig V. 2015. Treatment strategies that enhance the efficacy and selectivity of mitochondria-targeted anticancer agents. Int J Mol Sci 16:17394–17421.
76. Mukhopadhyay A, Ni L, Yang CS, Weiner H. 2005. Bacterial signal peptide recognizes HeLa cell mitochondrial import receptors and functions as a mitochondrial leader sequence. Cell Mol Life Sci 62:1890–1899.
77. Mullen AR, Wheaton WW, Jin ES, Chen PH, Sullivan LB, Cheng T, Yang Y, Linehan WM, Chandel NS, DeBerardinis RJ. 2012. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature 481:385–388.
78. Murphy MP. 2009. How mitochondria produce reactive oxygen species. Biochem J 417:1–13.
79. Murphy MP, Smith RA. 2000. Drug delivery to mitochondria: The key to mitochondrial medicine. Adv Drug Deliv Rev 41:235–250.
80. Murphy MP, Smith RA. 2007. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annual Rev Pharmacol Toxicol 47:629–656.
81. Ohta S. 2006. Contribution of somatic mutations in the mitochondrial genome to the development of cancer and tolerance against anticancer drugs. Oncogene 25:4768–4776.
82. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer SJ, Kunzer AR, Letai A, Li C, Mitten MJ, Nettesheim DG, Ng S, Nimmer PM, O'Connor JM, Oleksijew A, Petros AM, Reed JC, Shen W, Tahir SK, Thompson CB, Tomaselli KJ, Wang B, Wendt MD, Zhang H, Fesik SW, Rosenberg SH. 2005. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435:677–681.
83. Orrenius S, Zhivotovsky B, Nicotera P. 2003. Regulation of cell death: The calcium-apoptosis link. Nat Rev Mol Cell Biol 4:552–565.
84. Oudard S, Carpentier A, Banu E, Fauchon F, Celerier D, Poupon MF, Dutrillaux B, Andrieu JM, Delattre JY. 2003. Phase II study of lonidamine and diazepam in the treatment of recurrent glioblastoma multiforme. J Neurooncol 63:81–86.
85. Owens KM, Aykin-Burns N, Dayal D, Coleman MC, Domann FE, Spitz DR. 2012. Genomic instability induced by mutant succinate dehydrogenase subunit D (SDHD) is mediated by O2(-*) and H2O2. Free Radical Biol Med 52:160–166.
86. Pagliarini DJ, Wiley SE, Kimple ME, Dixon JR, Kelly P, Worby CA, Casey PJ, Dixon JE. 2005. Involvement of a mitochondrial phosphatase in the regulation of ATP production and insulin secretion in pancreatic beta cells. Mol Cell 19:197–207.
87. Park JS, Sharma LK, Li H, Xiang R, Holstein D, Wu J, Lechleiter J, Naylor SL, Deng JJ, Lu J, Bai Y. 2009. A heteroplasmic, not homoplasmic, mitochondrial DNA mutation promotes tumorigenesis via alteration in reactive oxygen species generation and apoptosis. Hum Mol Genet 18:1578–1589.
88. Pasquier J, Guerrouahen BS, Al Thawadi H, Ghiabi P, Maleki M, Abu-Kaoud N, Jacob A, Mirshahi M, Galas L, Rafii S, Le Foll F, Rafii A. 2013. Preferential transfer of mitochondria from endothelial to cancer cells through tunneling nanotubes modulates chemoresistance. J Transl Med 11:94.
89. Pavlides S, Whitaker-Menezes D, Castello-Cros R, Flomenberg N, Witkiewicz AK, Frank PG, Casimiro MC, Wang C, Fortina P, Addya S, Pestell RG, Martinez-Outschoorn UE, Sotgia F, Lisanti MP. 2009. The reverse Warburg effect: Aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle 8:3984–4001.
90. Pelicano H, Feng L, Zhou Y, Carew JS, Hileman EO, Plunkett W, Keating MJ, Huang P. 2003. Inhibition of mitochondrial respiration: A novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J Biol Chem 278:37832–37839.
91. Penta JS, Johnson FM, Wachsman JT, Copeland WC. 2001. Mitochondrial DNA in human malignancy. Mutation Res 488:119–133.
92. Petros JA, Baumann AK, Ruiz-Pesini E, Amin MB, Sun CQ, Hall J, Lim S, Issa MM, Flanders WD, Hosseini SH, Marshall FF, Wallace DC. 2005. MtDNA mutations increase tumorigenicity in prostate cancer. Proc Natl Acad Sci USA 102:719–724.
93. Polyak K, Li Y, Zhu H, Lengauer C, Willson JK, Markowitz SD, Trush MA, Kinzler KW, Vogelstein B. 1998. Somatic mutations of the mitochondrial genome in human colorectal tumours. Nat Genet 20:291–293.
94. Qing G, Li B, Vu A, Skuli N, Walton ZE, Liu X, Mayes PA, Wise DR, Thompson CB, Maris JM, Hogarty MD, Simon MC. 2012. ATF4 regulates MYC-mediated neuroblastoma cell death upon glutamine deprivation. Cancer Cell 22:631–644.
95. Ross MF, Kelso GF, Blaikie FH, James AM, Cocheme HM, Filipovska A, Da Ros T, Hurd TR, Smith RA, Murphy MP. 2005. Lipophilic triphenylphosphonium cations as tools in mitochondrial bioenergetics and free radical biology. Biochemistry (Mosc) 70:222–230.
96. Rossignol R, Faustin B, Rocher C, Malgat M, Mazat JP, Letellier T. 2003. Mitochondrial threshold effects. Biochem J 370:751–762.
97. Rossignol R, Gilkerson R, Aggeler R, Yamagata K, Remington SJ, Capaldi RA. 2004. Energy substrate modulates mitochondrial structure and oxidative capacity in cancer cells. Cancer Res 64:985–993.
98. Sabharwal SS, Schumacker PT. 2014. Mitochondrial ROS in cancer: Initiators, amplifiers or an Achilles’ heel? Nat Rev Cancer 14:709–721.
99. Samper E, Nicholls DG, Melov S. 2003. Mitochondrial oxidative stress causes chromosomal instability of mouse embryonic fibroblasts. Aging Cell 2:277–285.
100. Shay JW, Werbin H. 1987. Are mitochondrial DNA mutations involved in the carcinogenic process? Mutat Res 186:149–160.
101. Shidara Y, Yamagata K, Kanamori T, Nakano K, Kwong JQ, Manfredi G, Oda H, Ohta S. 2005. Positive contribution of pathogenic mutations in the mitochondrial genome to the promotion of cancer by prevention from apoptosis. Cancer Res 65:1655–1663.
102. Simons AL, Ahmad IM, Mattson DM, Dornfeld KJ, Spitz DR. 2007. 2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. Cancer Res 67:3364–3370.
103. Singh KK. 2004. Mitochondrial dysfunction is a common phenotype in aging and cancer. Ann NY Acad Sci 1019:260–264.
104. Singh KK, Ayyasamy V, Owens KM, Koul MS, Vujcic M. 2009. Mutations in mitochondrial DNA polymerase-gamma promote breast tumorigenesis. J Hum Genet 54:516–524.
105. Skulachev VP. 2007. A biochemical approach to the problem of aging: “Megaproject” on membrane-penetrating ions. The first results and prospects. Biochemistry (Mosc) 72:1385–1396.
106. Sloan EK, Ciocca DR, Pouliot N, Natoli A, Restall C, Henderson MA, Fanelli MA, Cuello-Carrion FD, Gago FE, Anderson RL. 2009. Stromal cell expression of caveolin-1 predicts outcome in breast cancer. Am J Pathol 174:2035–2043.
107. Smolkova K, Bellance N, Scandurra F, Genot E, Gnaiger E, Plecita-Hlavata L, Jezek P, Rossignol R. 2010. Mitochondrial bioenergetic adaptations of breast cancer cells to aglycemia and hypoxia. J Bioenerg Biomembr 42:55–67.
108. Smolkova K, Plecita-Hlavata L, Bellance N, Benard G, Rossignol R, Jezek P. 2011. Waves of gene regulation suppress and then restore oxidative phosphorylation in cancer cells. Int J Biochem Cell Biol 43:950–968.
109. Snow BJ, Rolfe FL, Lockhart MM, Frampton CM, O'Sullivan JD, Fung V, Smith RA, Murphy MP, Taylor KM. 2010. A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease. Mov Disord 25:1670–1674.
110. Sobenin IA, Mitrofanov KY, Zhelankin AV, Sazonova MA, Postnov AY, Revin VV, Bobryshev YV, Orekhov AN. 2014. Quantitative assessment of heteroplasmy of mitochondrial genome: Perspectives in diagnostics and methodological pitfalls. BioMed Res Int 2014:292017.
111. Spees JL, Olson SD, Whitney MJ, Prockop DJ. 2006. Mitochondrial transfer between cells can rescue aerobic respiration. Proc Natl Acad Sci USA 103:1283–1288.
112. Sudarshan S, Sourbier C, Kong HS, Block K, Valera Romero VA, Yang Y, Galindo C, Mollapour M, Scroggins B, Goode N, Lee MJ, Gourlay CW, Trepel J, Linehan WM, Neckers L. 2009. Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1alpha stabilization by glucose-dependent generation of reactive oxygen species. Mol Cell Biol 29:4080–4090.
113. Sullivan LB, Martinez-Garcia E, Nguyen H, Mullen AR, Dufour E, Sudarshan S, Licht JD, Deberardinis RJ, Chandel NS. 2013. The proto-oncometabolite fumarate binds glutathione to amplify ROS-dependent signaling. Mol Cell 51:236–248.
114. Supinski GS, Murphy MP, Callahan LA. 2009. MitoQ administration prevents endotoxin-induced cardiac dysfunction. Am J Physiol Regul Integr Comp Physiol 297:R1095–R1102.
115. Suzuki S, Naito A, Asano T, Evans TT, Reddy SA, Higuchi M. 2008. Constitutive activation of AKT pathway inhibits TNF-induced apoptosis in mitochondrial DNA-deficient human myelogenous leukemia ML-1a. Cancer Lett 268:31–37.
116. Tan AS, Baty JW, Dong LF, Bezawork-Geleta A, Endaya B, Goodwin J, Bajzikova M, Kovarova J, Peterka M, Yan B, Pesdar EA, Sobol M, Filimonenko A, Stuart S, Vondrusova M, Kluckova K, Sachaphibulkij K, Rohlena J, Hozak P, Truksa J, Eccles D, Haupt LM, Griffiths LR, Neuzil J, Berridge MV. 2015. Mitochondrial genome acquisition restores respiratory function and tumorigenic potential of cancer cells without mitochondrial DNA. Cell Metab 21:81–94.
117. Thornburg JM, Nelson KK, Clem BF, Lane AN, Arumugam S, Simmons A, Eaton JW, Telang S, Chesney J. 2008. Targeting aspartate aminotransferase in breast cancer. Breast Cancer Res 10:R84.
118. Trachootham D, Alexandre J, Huang P. 2009. Targeting cancer cells by ROS-mediated mechanisms: A radical therapeutic approach? Nat Rev Drug Discov 8:579–591.
119. Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, Pelicano H, Chiao PJ, Achanta G, Arlinghaus RB, Liu J, Huang P. 2006. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 10:241–252.
120. van Vliet AR, Verfaillie T, Agostinis P. 2014. New functions of mitochondria associated membranes in cellular signaling. Biochim Biophys Acta 1843:2253–2262.
121. Verschoor ML, Ungard R, Harbottle A, Jakupciak JP, Parr RL, Singh G. 2013. Mitochondria and cancer: Past, present, and future. BioMed Res Int 2013:612369.
122. Vicha A, Taieb D, Pacak K. 2014. Current views on cell metabolism in SDHx-related pheochromocytoma and paraganglioma. Endocr Relat Cancer 21:R261–R277.
123. Wallace DC. 1999. Mitochondrial diseases in man and mouse. Science 283:1482–1488.
124. Wallace DC. 2005. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: A dawn for evolutionary medicine. Ann Rev Genet 39:359–407.
125. Wallace DC. 2012. Mitochondria and cancer. Nat Rev Cancer 12:685–698.
126. Wang X, Gerdes HH. 2015. Transfer of mitochondria via tunneling nanotubes rescues apoptotic PC12 cells. Cell Death Differ 22:1181–1191.
127. Warburg O. 1928. The chemical constitution of respiration ferment. Science 68:437–443.
128. Warburg O, Wind F, Negelein E. 1927. The metabolism of tumors in the body. J Gen Physiol 8:519–530.
129. Ward PS, Thompson CB. 2012. Metabolic reprogramming: A cancer hallmark even warburg did not anticipate. Cancer Cell 21:297–308.
130. Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, Lopez M, Kalyanaraman B, Mutlu GM, Budinger GR, Chandel NS. 2010. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci USA 107:8788–8793.
131. Weinberg SE, Chandel NS. 2015. Targeting mitochondria metabolism for cancer therapy. Nature Chem Biol 11:9–15.
132. West AP, Shadel GS, Ghosh S. 2011. Mitochondria in innate immune responses. Nat Rev Immunol 11:389–402.
133. Williams GS, Boyman L, Lederer WJ. 2015. Mitochondrial calcium and the regulation of metabolism in the heart. J Mol Cell Cardiol 78:35–45.
134. Wise DR, Ward PS, Shay JE, Cross JR, Gruber JJ, Sachdeva UM, Platt JM, DeMatteo RG, Simon MC, Thompson CB. 2011. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of alpha-ketoglutarate to citrate to support cell growth and viability. Proc Natl Acad Sci USA 108:19611–19616.
135. Witkiewicz AK, Dasgupta A, Sotgia F, Mercier I, Pestell RG, Sabel M, Kleer CG, Brody JR, Lisanti MP. 2009. An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol 174:2023–2034.
136. Yadav N, Chandra D. 2013. Mitochondrial DNA mutations and breast tumorigenesis. Biochim Biophys Acta 1836:336–344.
137. Yakes FM, Van Houten B. 1997. Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress. Proc Natl Acad Sci USA 94:514–519.
138. Yamada Y, Akita H, Kamiya H, Kogure K, Yamamoto T, Shinohara Y, Yamashita K, Kobayashi H, Kikuchi H, Harashima H. 2008. MITO-Porter: A liposome-based carrier system for delivery of macromolecules into mitochondria via membrane fusion. Biochim Biophys Acta 1778:423–432.
139. Yang Y, Bazhin AV, Werner J, Karakhanova S. 2013a. Reactive oxygen species in the immune system. Int Rev Immunol 32:249–270.
140. Yang Y, Karakhanova S, Werner J, Bazhin AV. 2013b. Reactive oxygen species in cancer biology and anticancer therapy. Curr Med Chem 20:3677–3692.
141. Yu M. 2011. Generation, function and diagnostic value of mitochondrial DNA copy number alterations in human cancers. Life Sci 89:65–71.
142. Yuan Y, Wang W, Li H, Yu Y Tao J, Huang S, Zeng Z. 2015. Nonsense and missense mutation of mitochondrial ND6 gene promotes cell migration and invasion in human lung adenocarcinoma. BMC Cancer 15:346.
143. Zamzami N, Kroemer G. 2003. Apoptosis: Mitochondrial membrane permeabilization-the (w) hole story? Curr Biol 13:R71–R73.
144. Zastawny TH, Dabrowska M, Jaskolski T, Klimarczyk M, Kulinski L, Koszela A, Szczesniewicz M, Sliwinska M, Witkowski P, Olinski R. 1998. Comparison of oxidative base damage in mitochondrial and nuclear DNA. Free Radical Biol Med 24:722–725.
145. Zhang E, Zhang C, Su Y, Cheng T, Shi C. 2011. Newly developed strategies for multifunctional mitochondria-targeted agents in cancer therapy. Drug Discov Today 16:140–146.
146. Zhdanov AV, Dmitriev RI, Golubeva AV, Gavrilova SA, Papkovsky DB. 2013. Chronic hypoxia leads to a glycolytic phenotype and suppressed HIF-2 signaling in PC12 cells. Biochim Biophys Acta 1830:3553–3569.
147. Zong WX, Thompson CB. 2006. Necrotic death as a cell fate. Genes Dev 20:1–15.